Form 13-F position report

AKOYA BIOSCIENCES INC

Reported by MORGAN STANLEY

AKYA CUSIP 00974H104 Manager CIK 0000895421

Reported 37,220 shares, up 7,370 (24.7%) from the prior quarter.

Reported value 12.6%; share count 24.7% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2023
Shares 37,220 Quarter-end amount reported
Reported value $275,057 Fair value at quarter end
Consecutive quarters held 9 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 435000
2022-03-31 443000
2022-06-30 650000
2022-09-30 532000
2022-12-31 413424
2023-03-31 244174
2023-06-30 275057
2023-09-30 155793
2023-12-31 423580
2024-03-31 299063
2024-06-30 253152
2024-09-30 463518
2024-12-31 297172
2025-03-31 158039
2025-06-30 107925
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for AKOYA BIOSCIENCES INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -83,019 (-100.0%) 0 $0 2025-11-14
Q2 2025 Reduced 83,019 -30,679 (-27.0%) < 0.01% $107,925 2025-08-15
Q1 2025 Reduced 113,698 -16,071 (-12.4%) < 0.01% $158,039 2025-05-15
Q4 2024 Reduced 129,769 -40,642 (-23.8%) < 0.01% $297,172 2025-02-14
Q3 2024 Added 170,411 +62,227 (57.5%) < 0.01% $463,518 2024-11-14
Q2 2024 Added 108,184 +44,418 (69.7%) < 0.01% $253,152 2024-08-14
Q1 2024 Reduced 63,766 -23,033 (-26.5%) < 0.01% $299,063 2024-05-15
Q4 2023 Added 86,799 +53,295 (159.1%) < 0.01% $423,580 2024-02-13
Q3 2023 Reduced 33,504 -3,716 (-10.0%) < 0.01% $155,793 2023-11-15
Q2 2023 Added 37,220 +7,370 (24.7%) < 0.01% $275,057 2023-08-14
Q1 2023 Reduced 29,850 -13,350 (-30.9%) < 0.01% $244,174 2023-05-15
Q4 2022 Reduced 43,200 -2,063 (-4.6%) < 0.01% $413,424 2023-02-14
Q3 2022 Reduced 45,263 -5,353 (-10.6%) < 0.01% $532,000 2022-11-14
Q2 2022 Added 50,616 +10,404 (25.9%) < 0.01% $650,000 2022-08-15
Q1 2022 Added 40,212 +11,751 (41.3%) < 0.01% $443,000 2022-05-13
Q4 2021 Reduced 28,461 -94,616 (-76.9%) < 0.01% $435,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

83 managers reported AKOYA BIOSCIENCES INC for Q2 2023.

Managers reporting AKOYA BIOSCIENCES INC in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Blue Water Life Science Advisors LP Added 4,697,785 +2,600,000 23.43% $34,716,631 7 qtrs
Polar Capital Holdings Plc Added 1,515,470 +200,000 0.06% $11,199,323 9 qtrs
VANGUARD GROUP INC Added 1,309,130 +321,357 < 0.01% $9,674,471 9 qtrs
BlackRock Inc Added 1,189,850 +193,305 < 0.01% $8,792,991 9 qtrs
Board of Trustees of The Leland Stanford Junior University Added 620,434 +1 0.46% $4,584,999 9 qtrs
Uniplan Investment Counsel Inc Added 543,216 +78,012 0.29% $4,014,000 4 qtrs
MILLENNIUM MANAGEMENT LLC Added 507,069 +386,429 < 0.01% $3,747,240 9 qtrs
SVB WEALTH LLC Unchanged 499,917 0 0.07% $3,694,387 3 qtrs
Granahan Investment Management LLC Reduced 482,196 -114,923 0.11% $3,563,428 5 qtrs
Parkman Healthcare Partners LLC Added 471,000 +269,615 0.6% $3,480,690 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
18,579
Shared
118
None
18,523

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.